Edward Bilsky PhD
Dr. Edward Bilsky currently serves as the Provost and Chief Academic Officer at Pacific Northwest University of Health Sciences.
He received a Ph.D. in Pharmacology and Toxicology from the University of Arizona Colleges of Medicine and Pharmacy in 1996, with a concentration in opioid pharmacology, pain and addiction. As an assistant professor at the University of Northern Colorado, he received that institution’s highest honor, the Faculty Member of the Year in the spring of 2001, for his outstanding teaching, research and service to students. In the fall of 2001, he joined the faculty at the University of New England where he became a tenured Professor of Pharmacology and was the founding Director of the Center of Excellence in Neuroscience (CEN). The CEN incorporated research, education and outreach into its mission and vision and has created a robust community of neuroscientists and other scholars who are making meaningful contributions to their discipline, institution and community. More recently, he served as the Vice President for Research and Scholarship at UNE from 2011-2016. Under his leadership, UNE substantially grew the amount of external funding and scholarly output of the faculty and students, including major NIH and other health-related grants.
Dr. Bilsky engages a broad group of audiences on a variety of topics related to the neurobiology of pain, pain management and addiction to students in colleges of Osteopathic Medicine, Dental Medicine, Health Professions, Arts and Sciences and Pharmacy. He was awarded the 2011 AOA Research Mentor of the Year Award, was a finalist for the 2014 Council on Undergraduate Research Fellows award, a recipient of the Faculty for Undergraduate Neuroscience Lifetime Achievement Award and the 2014 Patient Advocacy Award from the American Academy of Pain Medicine. Dr. Bilsky’s laboratory conducts translational research in the areas of pain, addiction and other neurological disorders. He has received over 6 million dollars in extramural funding to his own laboratory through a variety of federal, state and private grants and contracts including the National Institutes of Health, the Office of Naval Research and biotechnology/pharmaceutical companies. He has published over 80 peer-reviewed publications in leading journals, and has presented nationally and internationally in a variety of different venues. Dr. Bilsky co-founded two biotechnology companies that developed novel analgesics and other drugs to help manage opioid side effects. Part of this work brought a novel opioid antagonist into clinical trials. Both companies received SBIR phase I and II funding, and Dr. Bilsky has reviewed SBIRs and U grants for NIH study sections. As an expert in opioid pharmacology and early-stage drug discovery and development, he collaborates with scientists around the world and frequently consulted and conducted contracted work with biotechnology and pharmaceutical companies that have programs in analgesia and pain medicine.